First Postpartum Depression Drug Approved by FDA Postpartum depression can be devastating for new moms. It affects 1 in 9 women. Now, a drug has finally been approved to treat it. The FDA has approved intravenous infusions of brexanolone, which will be marketed as Zulresso. The treatment requires a
60-hour IV drip. Mild side effects such as headache, dizziness
and excessive sleepiness may occur. But the drug, available in June, may have barriers for some women. Sage Therapeutics confirmed that the drug could be priced around $20,000 to $35,000 per treatment. Dr. Tiffany Farchione, FDA Division of Psychiatry Products